Ekgaluck Wanothayaroj

Ekgaluck Wanothayaroj

Auto-generated profile, based on publicly available information

Ekgaluck Wanothayaroj

Diabetes and Thyroid Center, Theptarin Hospital, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2024 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
TSThanompong Sathienluckana
Thanompong Sathienluckana
SPSirinoot Palapinyo
Sirinoot Palapinyo
KYKitiyot Yotsombut
Kitiyot Yotsombut
EWEkgaluck Wanothayaroj
Ekgaluck Wanothayaroj
PSPasiri Sithinamsuwan
Pasiri Sithinamsuwan
NSNaeti Suksomboon
Naeti Suksomboon
This consensus guidance is for community pharmacists in diabetic peripheral neuropathy (DPN) management with a combination of neurotropic B vitamins. A multidisciplinary team including endocrinology, neurology, and pharmacy from Thailand discussed and aligned the practical scheme of DPN management in the community pharmacy setting, using the literature review and having face-to-face meeting. Five major statements have been endorsed as consensus recommendations for DPN care with strong acknowledgment. The aims of DPN management included reducing symptoms and the risk of complications, minimising adverse reactions from treatment regimens, and improving patients’ knowledge and adherence to the treatment strategies. An initial screening process using a 7 items interview of Douleur Neuropathique 4 (DN4) questionnaire should be implemented to identify patients at risk of developing DPN. Subsequently, pharmacologic, and non-pharmacologic treatment should be employed based on patient-centered care. An interesting approach is combination of neurotropic B vitamins, which may be used as monotherapy or combination therapy to control DPN symptoms. The combined therapy potentially exhibits a synergistic effect and improves patient adherence. The consensus would be further considered in context of harmonisation of routine practice and country requirements.

2 September 2020 in Journal of Clinical & Translational Endocrinology
Verified
Journal Article
Open access
KKKrittadhee Karndumri
Krittadhee Karndumri
YTYotsapon Thewjitcharoen
Yotsapon Thewjitcharoen
WCWaralee Chatchomchuan
Waralee Chatchomchuan
SPSriurai Porramatikul
Sriurai Porramatikul
SKSirinate Krittiyawong
Sirinate Krittiyawong
THThep Himathongkam
Thep Himathongkam
Background: Thyrotoxic periodic paralysis (TPP) is a unique manifestation of Graves’ disease. While it is uncommon in Asian, it is extremely rare in Caucasian patients (0.1–0.2%). Previous studies suggested that TPP indicate more severity of Graves’ disease and definitive treatments should be used to prevent relapses. Aim: To describe clinical features and impact of first-line treatment on long-term outcomes of TPP patients. Method: A retrospective cohort study over 35 years (1985–2019) of TPP from Graves’ disease patients was conducted. All cases were analyzed and their clinical courses were compared between those who received anti-thyroid drugs (ATD) versus radioactive iodine (RAI) as a primary treatment. None of them underwent surgery. Results: A total of 2964 hyperthyroid Graves’ disease patients were treated and followed-up at least 3 months over the study period. TPP was identified in 63 cases (2.1%) of all patients. There were 60 males and only 3 females with age at presentation of 35.0 ± 8.2 years. TPP was the first presentation of hyperthyroid Graves’ disease in 82.5% of them. During the acute attack of TPP, all patients presented with bilateral lower limb flaccid weaknesses with median serum potassium of 2.1 mmol/L. No fatal TPP cases were found. RAI was selected as primary treatment in 27 patients (42.9%). Nearly all RAI-treated patients rendered hypothyroidism with the median RAI dose at 15 mCi. No patients who were in remission after RAI treatment developed recurrent attack of TPP. In the remaining 36 ATD-treated patients with mean follow-up time at 9.1 years, relapse was found in 10 patients (27.8%) after the drug discontinuation and 6 patients suffered recurrent TPP. Only 8 ATD-treated TPP patients (22.2%) went into remission. Conclusions: TPP is a rare complication of hyperthyroid Graves’ disease. Definitive treatment with RAI or thyroidectomy should be employed to prevent relapse and further attacks of TPP.

6 May 2017 in Journal of Clinical & Translational Endocrinology
Verified
Journal Article
Open access
PDF file
YTYotsapon Thewjitcharoen
Yotsapon Thewjitcharoen
SKSirinate Krittiyawong
Sirinate Krittiyawong
SPSriurai Porramatikul
Sriurai Porramatikul
EWEkgaluck Wanothayaroj
Ekgaluck Wanothayaroj
NLNampetch Lekpittaya
Nampetch Lekpittaya
THThep Himathongkam
Thep Himathongkam
Measurement of serum IgG4 had been suggested to distinguish the unique subtypes of autoimmune thyroid disease (AITD) which demonstrated patterns of fluctuating between hyperthyroidism and hypothyroidism. However, the clinical utility of serum IgG4 measurement is inconclusive due to few studies having addressed these unusual patients compared with the specificity of serum IgG4 in healthy patients.